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1. Introduction
The β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is an important regulator
for the production of amyloid plaques, a characteristic of the Alzheimer’s disease (AD)
brain. The proteolytic cleavage of the amyloid precursor protein (APP), by BACE1, produces
an insoluble amyloid-β (Aβ) fragment which has the ability to aggregate and migrate onto
the dendrites and cell body of neuronal cells, initiating chronic immune responses of inflam‐
mation and microglia activation.
The cleavage of Aβ fragments trigger a feedback system that complements production num‐
bers. This increases Aβ loading to such an extent that it exceeds the defences required for
natural elimination. The fragments aggregate, developing into an insoluble plaque that has
the ability to effect normal functioning by causing dysfunction. Without early identification
and effective inhibition of this pathogenic pathway, the disease is anticipated to become
more widespread with an aging population, in which AD is most prevalent.
Attempts to inhibit BACE1 have been relatively fruitless with most therapeutic trials being
aborted in the early stages. A number of obstacles can be detrimental to the ability of an in‐
hibitor like solubility, bioavailability, potency and effectiveness. In addition to the complexi‐
ty, there are also a number of substrates cleaved by BACE1 which are important in other
pathways like voltage gated sodium channels and axon myelination [1, 2]. This can create
adverse reactions beyond the reduction of plaques.
Inhibitors of BACE1 have, so far, looked at active-site mimics that diverge from small and
large molecules to short peptidic structures and expression modulators. Other approaches
look to utilize technology with modelling software to determine the BACE1 3D structure
and formulate an effective inhibitor via domain analysis. The underlying issue is translat‐
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ing an analytically based, site-directed mimic into a potential inhibitor with pharmaceuti‐
cal  integrity.  This  process  is  generally  thwarted  by  the  blood  brain  barrier  (BBB),  a
specialized endothelium that separates systemic blood flow from the central nervous sys‐
tem (CNS). The aim is to fabricate an inhibitor that can pass through the BBB whilst main‐
taining structure and function.
The importance of BACE1 and the influence it has on AD, has been investigated thoroughly
since it was first identified in 1999. The enzyme is an intricate part of Aβ cleavage and pla‐
que formation instigating that inhibition could be the mechanism for relief in AD. In this
chapter, we will summarize the structure and function of BACE1 and identify past attempts
at its inhibition. The identification of important features regarding the protein-enzyme
cleavage of APP will aid the understanding of the process and help theorize future perspec‐
tives of research.
2. Neurodegenerative disorders
Neurodegenerative disorders cover a wide range of brain conditions relating to the dam‐
age or death of neuronal cells [3]. Clinical characterisation suggests a regression in struc‐
ture and function of the brain and central nervous system which is usually the final stage
of a preceding period of neuronal dysfunction [4].  Specifically,  dementia is  of particular
significance because of the devastating influence it bares on an ageing population and as
the life expectancy of the general public increases, disease rates are predicted to escalate
accordingly.
The burden of disease in relation to AD, the most predominant form of dementia, was calcu‐
lated to be 26.6 million cases worldwide in 2006 [5]. This figure implicated 34% of the popu‐
lation over the age of 65 and 45% over the age of 85. The World Health Organization revised
this figure in 2010 to incorporate dementia as a whole because of the difficulty to diagnose
the varieties of neurodegenerative disorders [6]. The worldwide incidence was tallied at ap‐
proximately 35.6 million with an estimated 7.7 million new cases annually instigating a new
case arising every 4 seconds. The significance of this in regards to AD is that it covers
60-70% of dementia cases [6]. These figures could be inflated further because most cases go
undiagnosed due to the requirement of post-mortem autopsy for confirmation.
The ripple effect of dementia extends far from those affected and into patient support net‐
works. The worldwide costs are estimated to be US$604 billion annually and as the number
of affected increases this number is expected to follow suit [6]. The chronic onset of the dis‐
ease indicates an eventual requirement for long term care. The financial burdens relating to
carers, as the disease evolves and symptoms increase with severity, the eventual require‐
ment for long term formal care is inevitable [7]. AD patients specifically require increased
supervision after diagnosis because of the increased risk of developing associated diseases
like cardiovascular disease, diabetes, and bone weakening [8].
AD is largely defined by chronic symptoms of progressive neuronal and synaptic apoptosis
in the cerebral cortex and subcortical regions of the brain [4]. The direct consequence is cel‐
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lular atrophy, which includes degeneration in the temporal and parietal lobes, parts of the
frontal cortex and cingulate gyrus [9, 10]. Progression of brain atrophy to well-defined brain
structures results in symptoms of delusions, hallucinations, agitation, depression, anxiety,
elation, apathy, disinhibition, irritability, aberrant motor behaviour and sleep disorders [11].
As the chronic nature of the disease progresses, the number of symptoms increases, becom‐
ing severely debilitating. Eventually, death results after long-term stress and reduction of
brain structure and function [9].
Currently there are a variety of different intervention strategies being investigated to reme‐
dy these debilitating pathologies and focus to reduce the cause of neuronal cell death. Up‐
wards of 100 irregular protein changes occur in a brain with AD, including hyperexpression,
fragmentation and phosphorylation [12]. A number of these irregular protein modifications
could be a result of degenerating neurons causing further damage to associated structures of
the central nervous system [12]. The overall progression of AD is however, not restricted to
the dysfunction of one mechanism. The number of different symptoms result from a con‐
glomerate of sporadic cellular events that, as a consequence, stimulate the disease. The trig‐
ger or initial changes are not entirely clear and do not occur simultaneously which adds to
the ambiguity of the disease.
Histopathological review of AD patients highlighted amyloid plaques and neurofibrillary
tangles (NFT) as the two significant characteristics of cerebral regression identifying them as
targets for the prevention of neuronal cell death [4, 13]. Investigation into the onset of NFTs
implicate the tau protein as the leading cause [14]. The tau protein becomes hyperphos‐
phorylated and releases from the intracellular microtubules decreasing structure and func‐
tion and causing axons to become dishevelled and dedifferentiated. These subsequent
microtubules bind together to become an insoluble fibre decreasing the ability of neurons to
transmit action potentials along the axon and neurotransmitters across the synapse [15]. Al‐
leviation from this facet of the disease is yet to be elucidated.
Amyloid plaque formation is characterized by an accumulation of amyloid-β (Aβ) sub-units
on the cell membrane of neurons that, as a result, cause a decrease in cellular function [16].
The progressive damage of amyloid plaques cause neuronal apoptosis by activating the
complement cascade and stimulating the membrane attack complex [17]. In developed cases
of AD, where there is a high concentration of Aβ, significant damage to the physical struc‐
ture of the brain can be a result of the immune response. The activation of the complement
cascade involves microglia and astrocytes, which have both protective and destructive at‐
tributes. The eventual outcome is apoptosis because of the overwhelming immune response,
which cannot be hindered by anti-inflammatory drugs [18]. The aggregations of Aβ deposits
are neurotoxic, insoluble and become vastly distributed around the brain as they increase in
numbers [19]. AD needs to be proactively prevented before amyloid plaque formation gains
the ability to manipulate regular brain function and cause irreversible brain damage.
Closer investigation of the AD brain will encounter a plethora of imperative neuronal cell
functions failures like synaptic failure [20], depletion of neurotransmitters [21], mitochondri‐
al dysfunction [22], decreased cholesterol metabolism [23], reduction of neurotrophin [24]
and axonal transport deficiencies [25] which can be classified as associated effects of the dis‐
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ease. These associated deficiencies become apparent with the onset of plaque formation,
which precedes tau deconstruction [26]. The repercussions of tau mutations are a character‐
istic of frontotemporal dementia (FTD) and Parkinson’s like defects rather than AD, which
makes plaque formation the focus of this chapter [27].
3. Amyloid plaque formation
Amyloid plaques were originally purified in the early 80s and examined to contain pepti‐
des of approximately 40 amino acids that aggregated as oligomers, later to be generically
named amyloid-beta (Aβ) [28]. Gene cloning and cDNA analysis of these monomers lead
to the realization that the origins of this peptide remained part of a larger precursor pro‐
tein [29]. This protein was later identified as the 695 amino acid, membrane bound cell re‐
ceptor,  amyloid  precursor  protein  (APP),  which  contained  the  Aβ  sequence  in  the
extracellular  domain  [30].  It  is  the  proteolytic  cleavage,  by  that  of  multiple  secretases,
which releases the Aβ product.
Proteolytic processing of APP occurs by one of two pathways, the amyloidogenic (pathogen‐
ic) or the non-amyloidogenic (non-pathogenic). Transport to the membrane via endosomes
is chaperoned by the intracellular adaptor protein, sorting nexin 17 (SNX17), where it be‐
comes available for processing by the secretases [31]. The determinant of amyloidogenesis
depends on the initial proteolytic cleavage in the extracellular space by either α- or β- secre‐
tase to create a soluble or insoluble fragment [19]. Cleavage of APP by the α-secretase, a pro‐
tein investigated as part of the disintigrin and metalloprotease (ADAM) family, cleaves APP
at the α-site releasing a soluble fragment sAPPα into the extracellular space [32]. This leaves
the C-terminal fragment of 83 amino acid residues (C-83), which is abruptly cleaved by γ-
secretase in the intramembrane space. This creates two subsequent fragments of the APP in‐
tracellular domain (AICD), released in the cytosol, and p3 which is released into the
extracellular space (Figure 1).
The amyloidogenic pathway also utilises APP as a target. This pathway is much like that of
the non-amyloidogenic pathway but instead α-secretase is substituted for β-secretase or beta
site APP converting enzyme 1 (BACE1). This enzyme also cleaves APP in the extracellular
space at the β-site, which is 18 amino acids towards the N-terminal, releasing a much shorter
soluble APP-β (sAPPβ) fragment [33, 34]. The remaining C-terminal fragment of 99 amino
acid residues (C-99) remains membrane bound until cleaved by γ-secretase. This releases
two fragments of AICD and Aβ (Figure 1).
The non-amyloidogenic pathway has the ability to nullify the amyloidogenic pathway by
simply having α-secretase cleave APP prior to that of BACE1. Since the α-site of APP is situ‐
ated between that of β- and γ-, the shorter p3 fragment is produced instead of Aβ. The ques‐
tion over competition for the cleavage of APP is still debated but there is evidence
suggesting that α-secretase nullification does not increase BACE1 activity in vitro [35]. The
subsequent fragments of sAPPα and AICD from the non-amyloidogenic pathway suggest a
purpose from the subsequent cleavage of APP. The sAPPα has shown to have neurotrophic
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and neuroprotective properties as well as promoting neurite expansion, synapse production
and cell adhesion, while AICD has a role in p53 expression and caspase 3 activation, both
associated with cell death, and in maintaining cellular actin dynamics [36-38]. This indicates
that the non-amyloidogenic cleavage of APP is imperative to the maintenance of neuronal
growth and function.
Figure 1. The cleavage of APP, depending whether by BACE1 or α-secretase, results in the production of an amyloid
plaque. The non-amyloidogenic pathway (non-pathogenic) begins with α-secretase, which releases sAPPα externally
from the endosome or cell membrane. The resulting C83 fragment is cleaved by γ-secretase in the intermembrane
space releasing both the AICD and p3 fragments. The release of p3 into the extracellular space is not associated with
plaque formation. Alternatively, the amyloidogenic (pathogenic) pathway begins with BACE1, instead of α-secretase,
and cleaves APP in a lipid raft region of the membrane. The sAPPβ released is considerably shorter than sAPPα and is
still released externally. The γ-secretase cleaves APP, the same as in the non-amyloidogenic pathway, but releases the
38-42 amino acid Aβ, and AICD. The externally released fragment, Aβ, has the capability to form an amyloid plaque by
aggregation.
The underlying difference between the two processes is the release of the Aβ and p3 frag‐
ments. The p3 is a shorter bi-product of the overall APP cleavage that has no known func‐
tion. However, the p3 fragment does not have the same ability to form stable oligomeric
intermediates like that of Aβ, which poses no threat to synaptic function instigating that it is
not the cause of amyloid plaques and is the reason for being the non-amyloidogenic path‐
way [39, 40]. This suggests that the longer Aβ peptide is the main neurotoxic fragment es‐
tablished from the APP fragment. The cleaved product becomes a peptide of 40 amino acid
residues but this can be varied between 38 and 42 depending on where the γ-secretase
cleaves APP.
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3.1. Amyloid-β
The γ-secretase complex is composed of four proteins: either one of presenilin 1 (PS1) or
presenilin 2  (PS2),  nicastrin (NCT),  anterior  pharynx-defective phenotype 1  (Aph-1)  and
presenilin enhancer 2 (Pen-2) [41]. The complex formation is initiated with a sub complex
that  forms  between  NCT  and  Aph-1  which  then  binds  to  one  of  the  PS  proteins  [42].
Pen-2 is used to activate the complex by selective binding [43]. Either PS can be used in
this process, with a 67% amino acid homology, including two separate aspartate residues,
asp257 and asp385, considered essential to catalytic ability, both have the ability to cleave
APP [44, 45]. Consequently, the decrease in availability of the γ-secretase components re‐
sults in a reduction of overall functionality, which can be targeted for use when consider‐
ing  inhibitors  and  the  vulnerabilities  of  this  complex  [46].  Mutation  to  either  the
presenilins, whether it be PS1 or PS2, can be seen as a potential threat to the production
of Aβ40-42, as one can compensate for the other.
The γ-secretase, being the consistent piece of the APP cleavage puzzle, is actually respon‐
sible for the diseased state in which plaques are formed. There are upwards of 100 mis‐
sense  mutations  identified  in  the  presenilins,  mostly  creating  the  difference  in  cleaved
fragments of APP [47]. The Aβ peptide created will be influenced with a varying overall
length  of  between  38-42  amino  acids  [19].  The  majority  of  these  mutations  influence  a
higher number of Aβ42 peptides, which have been found to be more amyloidogenic and
neurotoxic  [48,  49].  The wild-type presenilin  generates  Aβ40,  which is  considered to  be
less  neurotoxic  even  though  it  is  present  in  amyloid  plaques.  γ-secretase  cuts  down‐
stream  from  the  transmembrane  domain  into  the  ε-site  of  APP  and  therefore  slightly
shortens the AICD cleaving domain [50]. Aβ42 provides the basis for oligomerisation, fi‐
brillation and plaque generation,  even with  Aβ40 being found with  a  limited ability  to
protect neurons in mouse models [51]. The ratio of Aβ42/Aβ40 increases after the AD age
of onset but is still relatively low. However, with a binding affinity to Aβ40, fibrils can, as
a consequence, bind together, meaning there does not need to be a high concentration to
be effective [52].
The Aβ fragments are not always cleaved to the extracellular space either. There are a num‐
ber of conformations that Aβ fragments can take including monomers, which are found free
in neurons as a consequence of APP cleavage. Studies have also shown that fragments can
form the shape of α-helices, random coils and even as β-sheets in a neutual pH to add to the
complexity [53-56]. These individual fragments maintain the ability to block synaptic neuro‐
transmitter transfer and instigate an apoptotic response via activation of the p53 promoter
leading to cell death [57]. Alternatively, soluble Aβ oligomers have been referred to as Aβ-
derived diffusible ligands (ADDLs) that have the ability to aggregate into protofibrils,
spherical structures of 7-10 nm wide, that can have the ability to interrupt nerve signal
transduction leading to cell death [58]. Initial investigations into the Aβ fibrils showed there
was a toxic response from the neurons in which they were attached [59].
To target the Aβ fibrils, gene knockout studies of PS1 have found adverse reactions relat‐
ing to formation of the axial skeleton, neurogenesis and neuronal survival causing effect‐
ed mice to die late in embryogenesis [60]. These reactions however, can be attributed to a
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dysfunction of the Notch signalling pathway because of its involvement with cell prolifer‐
ation, apoptosis and myelin formation, not to mention it is a substrate of γ-secretase [61].
This indicates that there are a number of associated risks with nullifying γ-secretase that
with any inhibition,  the complex will  invariably prevent the cleavage of  two regulatory
pathways.
3.2. Neuroinflammation
The increase of intra and extracellular Aβ has a direct effect on the complement system
and the recruitment of microglia, instigating the activation of inflammatory mechanisms,
a trademark of stress on an Alzheimer’s brain [62]. The microglia, derived from the mes‐
enchyme and transferred to the CNS where proliferation occurs, are classified as the mac‐
rophages of the brain and regulate apoptotic cell abundance [63]. Stress incurred, mainly
by amyloid plaque formation, triggers an immune response which leads to the activation
of astrocytes and microglia to dismantle the ailing cell. The Aβ fragment has the ability to
activate this process via the receptor for advanced glycation end products (RAGE), a mul‐
ti-ligand member of the immunoglobulin family that is increased in production in an AD
brain, and by CD40, an inflammatory signalling receptor [64-66]. The general immune re‐
sponse is aimed at eliminating Aβ, removing disease ridden cells and restoring tissue in‐
tegrity  but  does  more  damage  when  it  becomes  of  a  chronic  nature.  The  activation  of
reactive oxygen species (ROS), prostaglandins, and pro-inflammatory cytokines are a char‐
acteristic of the chronic inflammation and neuronal dysfunction in AD [67].
The onset of AD encourages the migration of microglia to the plaque affected areas. Cul‐
tured microglia, from elderly human patients, showed this migration as they coupled with
Aβ for the purpose of deconstruction [68]. Similar findings were discovered in sections of
cortex tested in vitro for migration but growing evidence suggests that once endocytosed,
the microglia struggle to breakdown the Aβ, causing stress and functional changes to the
cell [68-70]. Additionally, the APP mRNA translation is upregulated in the event of trauma,
nerve damage and brain ischemia, which can be beneficial for the release of more AICD, but
can also result in the production of more Aβ [71-73]. BACE1 has also been found to be regu‐
lated by Aβ42 via the c-Jun N-terminal kinase (JNK) pathway, otherwise known as the
stress-activated signalling pathway which is important for the mediation of pro-inflammato‐
ry cytokines [74, 75]. This reiterates the important influence that a variety of stressors have
when responding to the amyloidogenic pathway and that there are many different path‐
ways that can be involved in the pathogenesis of amyloid plaques.
All aspects of the amyloid plaque progression relates back to the effectiveness of the BACE1
enzyme. Taking into consideration alternative BACE1 substrates, the proteolytic cleavage of
APP can be regulated with an inhibitor. The Aβ concentration increases as the disease gets
worse but could be diverted with the use of an effective pharmaceutical intervention. The
possibilities and implications will not be recognised until BACE1 is inhibited successfully in
vivo.
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4. BACE1
4.1. BACE1 production and natural degradation
The BACE1 enzyme (also called β-secretase, Asp2 or memapsin2) is developed in the endo‐
plasmic reticulum from a 501 amino acid, 60 kDa, immature precursor protein. The transfer
from the endoplasmic reticulum to the Golgi is dependent on the prodomain, which is re‐
moved by the proprotein convertase, furin [76]. At this stage the immature BACE1 can al‐
ready cleave APP so is not a true zymogen but the removal of the prodomain can double the
proteolytic effectiveness whilst increasing structural stability [77, 78]. The immature BACE1
is deacetylated and transformed in the golgi by post-translational modification into a type 1
transmembrane protein [79]. A bi-lobal structure is formed with two aspartate motifs
(D93TG and D289SG in a D-T/S-G-T/S conformation), which forms the active site that stimu‐
lates water molecules to hydrolyse APP peptide bonds, a defining characteristic of aspartic
proteases [80, 81]. The proteolytic ability of this motif is only limited by site-directed muta‐
genesis of the aspartate residues [81]. The active site remains an important structure of this
enzyme because of its supposed vulnerability. However, although it has been the focus of
inhibition studies since its highly contested discovery in 1999, no effective pharmaceutical
options have been elucidated since [34, 82-85]. The distinctiveness surrounding BACE1 is ex‐
posed when comparing it to other aspartic proteases and the contrasting characteristics of a
C-terminal cytosolic tail and a transmembrane domain.
The transfer from the Golgi to the cell membrane is mediated by transport vesicles because
BACE1 is membrane bound. The serine and di-leucine residues of BACE1 act as a signal for
the Golgi-localized γ-ear-containing ARF binding protein 1 (GGA1), a sorting protein that
aids the link between the transporting endosome and the cell membrane [86]. The endosome
provides an optimal transport vesicle because of its internal acidic nature (approximately
pH 4.5), a fundamental for the conformational shape and functionality of BACE1, but also
because it is much more stable environment for transporting proteins [87, 88]. Changes in
pH below 4.0 can have a negative effect on Wat1, a molecule considered to be the nucleo‐
phile with the ability to attack the carbonyl carbon of a peptide bond in the active site result‐
ing in the loss of functionality. Changes at the other end of the scale, above that of pH 7.0,
render the enzyme inactive and unable to cleave a substrate [87] (Figure 2A,B,C).
The active site placement is also vulnerable as it remains exposed to the extracellular space
once it makes the transition to the lipid bi-layer of the membrane where it concludes its in‐
tracellular transport. BACE1 becomes susceptible to post-translational modification, protein
to protein interactions or even inhibitor attachment because of its availability. It is here,
however, that the BACE1 enzyme comes into contact with the membrane bound APP [89].
In some instances, the help of increased cellular cholesterol producing lipid rafts helps im‐
prove the availability of APP for BACE1. So what is considered a negative of vulnerability of
the enzyme actually serves an important purpose in that a specific environment is created
for APP to become more available. The lipid rafts are formed as an essential membrane sta‐
bilizer of intermediate space but have also controversially, improved signal transduction
and intracellular trafficking ability of the cell [90].
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BACE1 is found in a number of tissues throughout the body but majority of expression is
found in the brain [91]. The levels of this expression have been of much debate due to con‐
flicting reports separating different tissues in which the samples were taken, animal or hu‐
man models and the use of controls [92]. The increase in expression could then be argued as
a reason for the uncontrollable aggregation of Aβ but reports of little or no increase in ex‐
pression of BACE1 instigates the influence of another factor is involved [93].
The natural degradation of BACE1 has been found to be involved the ubiquitin proteasome
pathway. BACE1 can be transported from endosomes to lysosomes by ubiquitination with
help from the sorting proteins, ADP ribosylation factor 6 (ARF6) and GGA3, another mem‐
ber of the GGA family [94-97]. The degradation by lysosomes is still ambiguous with an in‐
crease in BACE1 protein available in an AD brain, whilst there is little to no increase in
mRNA levels. The failed or impaired lysosome could be a contributing factor to the increase
in cellular Aβ or BACE1 could be getting recycled back into endosomes [93] (Figure 2D).
Figure 2. BACE1 Trafficking. BACE1 is constructed in the ER and processed, with the removal of the proBACE1 domain,
in the Golgi. A) BACE1 is a membrane bound protease and so is either exocytosed from the Golgi or transported to an
endosome with the help of the sorting protein GGA1. From here, the cleavage of APP to produce extracellular Aβ
takes place in the lipid raft region of the membrane. The synthesis of Aβ occurs through the amyloidogenic (patho‐
genic) pathway. B) Processing of APP can otherwise occur whilst present in the endosome and so can release Aβ into
the cytosoplasm. C) The Aβ can then either aggregate together or be endocytosed by lysosomes and degraded. D)
Once APP proteolysis has occurred, BACE1 is either internalized to endosomes via GGA1 and ARF6 or labelled with
ubiquitin and endocytosed. With assistance from the sorting protein, GGA3, the lysosomes will either recycle or de‐
grade BACE1.
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Recently, a natural inhibition of BACE1 has been found via the sAPPa fragment produced
from the non-amyloidogenic pathway [98]. The sAPPa, once produced from APP, has been
found to implicate its own cleavage. The findings showed that sAPPa can bind to BACE1
and interfere with the APP cleavage in a mouse model. This resulted in an overall reduction
in Aβ formation under physiological conditions. The consequence of this pathway being im‐
paired in any way, could result in a decrease in BACE1 production thus reducing the cleav‐
age of further units of APP. The sAPPa production or cellular concentration could be a
therapeutic intervention strategy in future research.
4.2. BACE2 and closely related proteins
BACE2 is a closely associated β-secretase to BACE1. Sequence analysis show amino acid res‐
idue similarities of ~45% and structural comparisons of 75% homology [99]. BACE2 is also
classified as an aspartic protease with the ability to cleave APP at the β-site [100]. In vitro
studies have also implicated BACE2 as a possible competitor of BACE1 for the cleavage of
the APP protein but it is not formally expressed in excess in the brain and does not compen‐
sate for the loss of BACE1 in gene knockout models in mice [89, 101]. In fact, over expression
of BACE2 has actually been found to reduce Aβ production in primary neuronal cultures
derived from APP transgenic mice. This could be caused by the ability of BACE2 to cleave
APP before BACE1 or because BACE2 cleaves a longer 79 residue Aβ fragment from APP,
which is closer to the cleaved fragment of α-secretase then that of BACE1 [89, 99].
Apart from the sequence homology, BACE2 is not primarily expressed in the brain. It is
more commonly expressed in the colon, kidney and pancreas, showing that whilst theo‐
retically still  having the ability to increase the pathogenesis of AD it is not considered a
threat to Aβ generation [100, 102]. BACE1 is the main amyloidogenic enzyme and still re‐
mains the major contributor to amyloid plaque formation but does show some sequence
homology with a number other aspartic proteases including renin and cathepsin D. These
homologs are generally used for selectivity testing with in vitro assays to confirm no un‐
wanted binding occurs.
4.3. Substrates of BACE1
The BACE1 protein is not solely defined to the cleavage of APP and has the ability to cleave
other proteins like amyloid like precursor proteins 1 and 2, APPε (which is another closely
related N-terminal product of APP), neuregulin-1 and -3 involved in axon myelination, β-
subunits of voltage gated sodium channels required for neuronal action potentials, P-selec‐
tin glycoprotein ligand-1 (PSGL-1), which regulates leukocyte adhesion in the inflammatory
process, the interleukin 1 receptor type-II (IL1-R2) and the low density lipoprotein receptor-
related protein 1(LLRP1), which is a multifunctional endocytic and signalling receptor [1, 2,
103-106]. With the use of an unbiased, quantitative proteomics method, the identification of
64 new potential substrates were elucidated. The majority of these were type I transmem‐
brane proteins but an added 3 glycophosphatidylinositol anchors and one type II transmem‐
brane protein were also identified, all of which are membrane bound [107]. This suggests
that BACE1 has a significant purpose in normal cellular functions but a number of these are
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yet to be characterised in vivo and subsequently cannot be verified as a substrate until this
time. With the interaction between BACE1 and APP being widely of interest in the preven‐
tion of AD, the actual damage by completely inhibiting the enzyme from normal function‐
ing could prove detrimental in its own right. APP may not even be the primary substrate of
the enzyme. Therefore, partial inhibition of BACE1 is all that may be required as an inter‐
vention therapy to normalize the enhanced BACE1 activity seen in AD patients.
Alternatively, both of the amyloidogenic creating enzymes, BACE1 and γ-secretase, have
alternative purposes relating to other substrates. Gene knockout studies in mouse models
produced the reaction of hyperactivity,  premature death and seizure like behaviours for
BACE1 whilst presenilin -/- mice displayed early neurodegenerative behaviours and an in‐
crease  of  Aβ species  which could possibly  be  due to  the  large number  of  substrates  in
which both are effective [108-111]. The γ-secretase complex is essential for the Notch sig‐
nalling pathway, which is important for the development of the nervous system and this
would also be in deficit if inhibited completely [112]. Likewise, the γ-secretase complex is
also required for the non-amyloidogenic pathway, suggesting that the complete inhibition
or deletion of these proteins will be detrimental to the homeostatic processing related to
normal development and function.
5. Challenges
5.1. Past BACE1 inhibitors
Inhibition of BACE1 has been the focus of many studies since it was discovered. The main
interest in this enzyme remains with the obvious involvement in plaque formation but also
to the positive intervention target for which it provides. Firstly, mouse models have shown
that without BACE1, Aβ is no longer produced, which indicates that if a product can reduce
the enzymatic ability of BACE1 then plaques will not be formed [109]. The enzyme has been
characterised and 3-D structure produced, which will allow for inhibitor modelling [80].
BACE1 also has the ability to bind to a wide variety of peptidic structures, while specific
binding is an attribute there is still access to the active site for potential targeting [113].
BACE1 is a part of the large aspartic protease family, which have had the success of at least
two members (renin and HIV protease-1(HIV-1) inhibited with success [114]. This shows
confidence that BACE1 is a viable option for inhibition and, if successful, could influence the
production of Aβ.
Drug intervention of AD is limited between therapeutic relief of symptoms and the preven‐
tion of the underlying etiology of the disease [115]. The treatment to minimise symptoms is
the only viable option for sufferers of AD. This method slows the decline of cognition, func‐
tion and behaviour but only masks the underlying neurodegeneration taking place [116].
The drugs currently available to treat AD are divided into two categories of cholinesterase
inhibitors and receptor antagonists [115].
Cholinesterase inhibitors attempt to prevent the metabolism of acetylcholine allowing the
neurotransmitter to maintain effect in the neuron [117]. Cholinesterase inhibiting drugs like
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donepezil, galantamine and revastigmine are only effective in the early stages of AD by al‐
lowing the retention of acetylcholine [115]. By inhibiting the hydrolysis of acetylcholine by
cholinesterase, once the neurotransmitter has crossed the synapse, the cholinergic neuron re‐
mains active [117]. This action becomes redundant when inadvertent progression of NFTs
interfere with the normal signal transmission of the axon [15]. Cholinesterase inhibitors have
shown that they can actually increase the amount of phosphorylated tau which can further
the progression of AD, minimising the effectiveness of the drug [118, 119].
The other pharmaceutical option is memantine, an uncompetitive N-methyl-D-aspartate
(NMDA) receptor antagonist, which prevents binding of the primary excitatory neurotrans‐
mitter in the brain, glutamate [120, 121]. As a result, glutamatergic overstimulation can oc‐
cur causing neuronal cell damage by increased localized calcium stores or excitotoxicity
[122]. Both drug options have important side effects and can only offer therapeutic relief of
symptoms and are not useful as a long-term intervention strategy.
Therapeutic relief by drugs like donepezil, galantamine and memantine are required to opti‐
mize the productivity of the brain whilst the disease progresses and cannot translate to a
definite cure. The production of Aβ is the basis of senile plaques and should be investigated
as an important therapeutic target. Theories suggest that by inhibiting BACE1 before it
cleaves APP, the formation of the beta amyloid residues would be reduced [123, 124]. To
prevent this process, inhibition would be paramount between the translation of BACE1 and
its binding to APP, before sAPPβ has been cleaved.
Modern drug discovery for a pharmaceutical intervention aims to hinder the BACE1 enzy‐
matic activity by exactly this process. Notable methods look at high-throughput screening
(HTS), fragment-based drug discovery (FBDD) and substrate-based inhibitors [125]. Howev‐
er, none of these methods have been successful in therapeutic trials. The more complex ap‐
proach, generally taken by larger pharmaceutical companies, relate to either the HTS
strategy or a FBDD approach. Both processes use a large library of complex compounds in
order to find a suitable hit followed by a long modification process to refine it into a suitable
chemical. Initial use of HTS sourced complex, high-molecular weight, compounds that were
difficult to manipulate. Potential therapeutic candidates showed strong oral availability and
good brain permeability but could not provide the standards of potency and selectivity for
therapeutic trials [125, 126]
The HTS method has been substituted by the FBDD approach because it uses smaller and
more specific compounds [127]. The screening of a fragment library is more appealing be‐
cause a higher hit ratio is produced and the options show favourable drug properties. The
main problem with the hit compounds is again, the low potency and selectivity. Often, frag‐
ments that showed promise were too small to be effective and have not provided any real
inhibition with the effectiveness required for therapeutic trials.
A large range of inhibitors are being researched including statins, primary, secondary and
tertiary  amines,  hydroethylamines  (HEA)  of  many  different  conformations,  arylamino
compounds and acyclic acylguanidines. Most of these compounds seek to act as transition
state mimics with a reduced peptidic structure that preclude them from the same scrutiny
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as other peptidic structures. To their detriment, hydroxyethylamine derivatives had poor
brain exposure, mainly because of p-glycoprotein (PgP) mediated efflux [128-130]. Bristol-
Myers Squibb produced a HEA-derivative that contained an indole and a 7-azoindole car‐
boxamide  but  struggled  to  maintain  brain  Aβ  levels  in  vivo  [131].  Unfortunately,  the
inhibitor showed a high potency in vitro that had an IC50 of 10 nM and a low affinity for
BACE2 and cathepsin D.
Another study has looked to hybridize the HEA isotere and replace the sulfonate ester
present in one molecule with the sulphonamide of another [132]. The result was a com‐
pound that had high potency IC50 of 15 nm to BACE1 that was able to bind to the hydro‐
phobic space of the active site. Unfortunately, this compound was able to bind to BACE2
which minimised the selectivity to BACE1. After problems with HEA structures and brain
penetration, Merck decided to use a macrocyclic inhibitor, produced by cross linking the P1
and P3 sidechains of an isophthalamide-based inhibitor. This process helped improve poten‐
cy but a bolus of 100 mg/kg fed to APP-YAC mouse model could only obtain Aβ decreases
of 25% in the first hour and 10% after the third [133].
From another perspective, BACE1 inhibitors have been manufactured from peptide sequen‐
ces by a substrate-based method. The initial peptide sequences showed promise with high
potency and selectivity but did not progress as a viable pharmaceutical target because of the
large, unstable products it produced. Branded OM99-2, this peptide was originally used to
determine many functions and shapes of BACE1 including the active site. Unfortunately, it
was too bulky to cross the BBB but maintained appropriate potency. Revision of this method
looked specifically at the structure and function of BACE1 in order to manufacture a peptide
sequence that would exploit its weaknesses [134]. It was designed to competitively inhibit
the binding regions and shut down the enzymatic properties. The finished product was a
long peptide upwards of 18 amino acid residues, which produced a high potency but was
not stable enough for use in therapeutic trials.
These studies made it clear that the peptidic structure would fulfil the desired properties re‐
quired for an inhibitor, the only issue being BBB transport which has motivated the research
into small molecules that can freely penetrate the brain. The potential inhibitor needs to be
lipophilic enough to permeate the BBB by passive diffusion via the use of a transporter that
can maintain entry to the CNS without exiting the same way. Another issue with the pep‐
tide inhibitors is the added convolution of ubiquity throughout the body. Since amino acids,
peptides and proteins are the building blocks of the human form and function, there is the
added complication of anonymity with other proteins and the possibility of unwanted bind‐
ing causing adverse reactions. If a severe enough reaction to the peptide is apparent, it
would be more detrimental then beneficial.
5.2. Crossing the blood brain barrier
The BBB is a network of brain capillaries that regulate the transfer of nutrients and co-fac‐
tors that are important to the functioning and maintenance of the brain. The conformation
begins with the lumen that is lined with a monolayer of capillary endothelial cells, held to‐
gether with tight gap junctions. This monolayer is complemented by pericytes for the pur‐
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pose of BBB-specific gene expression and inducing polarisation of the astrocyte end-feet
with the surrounding basal lamina [135]. The tight junctions are known to prevent the para‐
cellular diffusion of polar molecules from systemic circulation and brain parenchyma [136].
Complementing the endothelium are a number of compounds that defend against foreign
transfer like cytochrome p450 and glutathione S-transferase in conjunction with transporters
and the multidrug resistance associated proteins 1 and 2 (Mrp1/2) [137-139].
The defence mechanisms that protect the brain from systemic circulation become a chal‐
lenging  interference  when  fabricating  an  inhibitor,  especially  when  it  comes  to  testing
the administration of localised drug performance. The molecular weight threshold, which
is  a  relevant  property  of  all  membranes,  is  <450  Da  [140].  A  molecular  model  can  be
used to determine the effect of molecular size on membrane permeability and should be
a consideration when investigating an inhibitor  [141].  This  creates a  challenge that  goes
beyond the production of  protein specific  intervention strategies.  In the case of  BACE1,
there are a number of  different challenges,  as  previously mentioned,  influencing the in‐
hibition  of  APP  cleavage.  With  the  influence  of  the  BBB,  the  drug  will  be  required  to
maintain  an  ability  to  inhibit  BACE1 but  also  maintain  solubility  across  the  tight  junc‐
tions of vessel epithelium.
The natural functioning of the BBB is to maintain the tight junctions, for which it is idiosyn‐
cratic, but in order to transport a required drug, the concept of BBB disruption can be con‐
sidered. The relaxing of these junctions with hyperosmotic chemicals, for example, could be
enough to encourage transport to the brain. The only concern with this method is due to the
unfavourable uptake of plasma proteins, like albumin, which is toxic to astrocytes [142].
Consequently, it could also affect drug retention and enhance unwanted migration of other‐
wise rejected contaminants.
Another drastic, invasive technique involves drilling into the cranium and administering
the treatment via intracerebroventricular injection, intracerebral implantation and convec‐
tion  enhanced  diffusion.  While  all  are  incredibly  invasive  and  risky,  the  required  re‐
sponses  from  the  drug  once  applied  are  generally  not  that  positive  [143].
Intracerebroventricular  injection  specifically  has  been  found to  cause  haemorrhage  after
the  insertion  of  a  needle  into  the  brain  as  an  adverse  reaction  but  has  otherwise  has
shown  good  responses  [144].  This  suggests  these  invasive  techniques  are  questionable
and should be used with extreme caution.
The interesting, non-invasive, concept of lipid carriers has the most potential. The carriers
are attached to water soluble inhibitors, that cannot otherwise penetrate the BBB, and turn
them lipid soluble [145]. This will allow the transfer into the BBB but once across, the re‐
quirement to either shed the carrier or be able to function with it attached in order to main‐
tain functionality, becomes apparent. The naturally occurring, 60 amino acid, galanin-like
peptide (GALP) has the ability to cross the BBB where needed with the use of a saturable
transport system [146]. The glucose transporter (GLUT1) is another natural carrier system
that is used frequently as glucose is the main energy source of the brain [147]. If this method
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can be transformed for BACE1 inhibitors, the transfer of larger, more potent molecules with
an increased selectivity, could be achieved.
5.3. Transporters
The ability to transport potential inhibitors across the blood brain barrier can determine the
success or failure of the potential therapeutic intervention. The BBB has motivated the re‐
search base to investigate small <450 Da molecules that have the potential to pass the barrier
with minimal scrutiny. The issue being a lack of potency and selectivity in vivo which indicates
that a greater effectiveness could be achieved with a larger style inhibitor. The potential for
transporters could revolutionize the future of drug production by providing a medium in
which the larger more effective inhibitors can cross this barrier.
The earlier transporters aimed to cross the BBB by utilising the already formed channels
and receptors.  The idea was to couple an inhibitor with the specific  ligand of  a surface
receptor  like  that  of  the  H1  histone,  insulin,  insulin-like  growth  factors  or  transferrin
[148-151]. These systems can also work by binding the inhibitor to antibodies that identi‐
fy  surface  epitopes  already  present  in  the  BBB.  The  coupling  of  an  18mer  peptide  to
transferrin receptor specific antibodies were used to infiltrate the BBB via the transferrin
receptor for the inhibition of the rev gene of HIV-1 [152]. This study demonstrated a 15-
fold increase in transfer across the BBB. This system can be modified to display a num‐
ber of different biotinylated peptides specifically but could also be manipulated for other
effective compounds.
A more advanced method of targeted liposomes progresses from the inhibitor-ligand struc‐
ture to a colloidal carrier system. The concept still utilizes BBB receptors and channels but is
improved with an increase in the concentration of the inhibitor that it can carry. The liposo‐
mal system can hold >10,000 drug molecules [153]. The main question regarding this system
is the avoidance of opsonins which are members of the complement system and immuno‐
globulins that cover the colloidal particle and are able to activate phagocytosis. This method
has already been used to transfer monoclonal antibodies across the BBB [153]. The negative
of this system however, is the vulnerability to macrophages via opsonisation and the lack of
selectivity that liposomes have in regards to the brain and BBB. The targeted liposome sys‐
tem has already been used successfully to transfer sodium borocaptate in defence against
malignant glioma, which suggests that further research could provide a neurodegenerative
diseases template [154].
Alternatively, fullerenes are an allotropic form of carbon that form an arrangement of 60
atoms into the shape of a hollow sphere that is 1 nanometre in diameter and can be coupled
with an inhibitor [155]. These fullerene systems have shown promise in the fight against
chronic multiple sclerosis [156]. Whilst still in the early stages of research, recovery has been
attributed to a reduction in axon loss and demyelination in the spinal region of the CNS in a
mouse model. Another study has shown a reduction of infarct size in gerbils and rats with
the use of a hexasulfinonated C60 that was administered intravenously [157, 158]. Further
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research is required for the use in human studies but there is anticipation for its use against
the aggregation of Aβ.
6. Future perspectives
There are a number of exciting directions that future research will take to determine a safe
and effective treatment for AD. The regulation of internal pathways for the natural manage‐
ment of BACE1 activity is of key interest as it involves the crossroad from compound based,
active site mimics. The recent study identifying the sAPPα as a BACE1 modulator could mo‐
tivate the investigation of the broader pathway rather than focussing on the enzyme itself
[98]. Pathway regulation could reduce side effects and associated pathologies because of the
broad spectrum enzymes that envelope amyloidogenesis.
The implication of Aβ signalling in plaque formation is another concept for investigation for
the possibility of a feedback system. The promotion of Aβ proliferation could increase the
ability for a plaque to form as there is the availability to encourage the process. The applica‐
tion of a potential BACE1 inhibitor is rudimentary to the prevention of this disease because
of the potential to bypass the amyloidogenic pathway. With minimal Aβ production the
pressure released on the natural inflammatory defences would allow for the metabolism of
impeding plaques.
γ-secretase inhibitors have already been progressing to phase III clinical trials which seek to
influence the production of Aβ but maintain a number of important consequences that sur‐
round this process [159]. The implication of the Notch signalling pathway, important in ax‐
on myelination and apoptosis, could be more detrimental than plaque formation because of
the regulatory purpose in which it serves [112].
Merck have developed the MK-8931 inhibitor, which is currently undergoing phase II clini‐
cal trials [160]. It has already shown an ability to reduce Aβ40, Aβ42 and sAPPβ levels, is well
tolerated in vivo and shows minimal adverse reactions, which is encouraging for the <450 Da
compounds. Eli Lilly and AstraZeneca are also involved with BACE1 inhibitor clinical trials,
which will increase competition once results come to fruition. The opposing mentality be‐
hind BACE1 inhibitors, as small <450 Da compounds, could be the answer to years of at‐
tempts. The crossing of the barrier is not a major obstacle for this method but show
alternative hurdles of selectivity and bioavailability. This has created a race for a pharma‐
ceutically able inhibitor.
Alternatively, the membrane transporters concept for the advantage of allowing the transfer
of a range of different inhibitors, in a variety of doses, could produce a platform for a num‐
ber of different brain based diseases without being overly invasive. The BBB is an ominous
obstacle for a number of the earlier peptidic inhibitors, whilst showing a lot of promising
pharmaceutical attributes. The combination of the two technologies could provide the differ‐
ence required for drug penetration and selectivity.
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Once an inhibitor has been potentiated, the focus can move into research looking at plaque
clearing and neurogenesis that will aid regeneration of the AD brain. One option is the utiliza‐
tion of stem cells to replace lost brain mass by utilizing multi-potent adult neural stem cells
found in the subgranular and subventricular zones. The CNS has the ability to regenerate a
number of neuronal cell lines with astrocytes, oligodendrocytes, and functional neurons [161].
By utilizing these cell lines the brain could be “rebuilt” to maintain the structures affected by
the plaque formation. However, this would be implicated by numerous ethical challenges.
7. Conclusions
The onset of AD is relatively unknown, but early stages of the disease are met with the accu‐
mulation of amyloid plaques. The amyloidogenic pathway, mediated by the proteolytic
cleavage of APP, is the major focus for the alleviation of AD. BACE1, the defining enzyme of
this process, is responsible for the cleavage of the Aβ fragment. The determinant of fragment
length, 38-42 amino acids, is coordinated by γ-secretase. The focus is placed specifically on
fragments Aβ40 and Aβ42 because of the influence they maintain over plaque formation and
an increased affinity for aggregation.
Whilst there is an indication that γ-secretase maintains the ability to determine the severity
of plaque formation, there are a number of reasons to avoid inhibition, mainly because of its
involvement in the Notch pathway and the extreme consequences which brings to light the
cost outweighing the means. This is a hallmark of plaque formation as the enzymes in‐
volved have a number of substrates in different pathways that do not involve AD. This mo‐
tivates the notion of regulation, as opposed to complete inhibition, to aid the process
alleviating majority of the proteolysis.
The recent association between the cleaved product of APP by α-secretase, sAPPα, having
an influence on the amyloidogenic pathway adds another perspective to AD and the mecha‐
nisms relating to brain homeostasis. It prompts the idea of maintaining normal processing
as opposed to initiating inhibition. The BACE1 cleavage of APP is not a response, or trigger,
to AD progression but is fundamental in Aβ production, which implies that normal conser‐
vation is a natural process and regulation can be achieved with an external stimulus.
A large obstacle with potential BACE1 inhibitors is the ability to maintain the pharmaceuti‐
cal properties between in vitro and in vivo testing, namely the BBB. The transfer between the
Tight junctions of brain endothelium and the neuronal cells has defined the way BACE1 in‐
hibitors are engaged. The change from basic peptidic structures to that of small <450 Da
chemicals has solved one hurdle but has inadvertently created others. The original in vitro
studies of peptidic inhibitors maintained positive selectivity for BACE1 but were too bulky
for transport. The application of a BACE1 inhibitor, whatever structure it is formed from,
will be rudimentary in treating and alleviating the devastating prognosis of AD in the years
to come.
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